全文获取类型
收费全文 | 50727篇 |
免费 | 5361篇 |
国内免费 | 1590篇 |
专业分类
耳鼻咽喉 | 273篇 |
儿科学 | 1746篇 |
妇产科学 | 417篇 |
基础医学 | 6560篇 |
口腔科学 | 1634篇 |
临床医学 | 5345篇 |
内科学 | 10514篇 |
皮肤病学 | 1351篇 |
神经病学 | 2536篇 |
特种医学 | 890篇 |
外国民族医学 | 5篇 |
外科学 | 3784篇 |
综合类 | 8554篇 |
现状与发展 | 4篇 |
一般理论 | 1篇 |
预防医学 | 3118篇 |
眼科学 | 858篇 |
药学 | 5098篇 |
29篇 | |
中国医学 | 3574篇 |
肿瘤学 | 1387篇 |
出版年
2024年 | 65篇 |
2023年 | 1011篇 |
2022年 | 1156篇 |
2021年 | 2274篇 |
2020年 | 2311篇 |
2019年 | 1965篇 |
2018年 | 1869篇 |
2017年 | 2133篇 |
2016年 | 2301篇 |
2015年 | 2067篇 |
2014年 | 3772篇 |
2013年 | 4142篇 |
2012年 | 3890篇 |
2011年 | 3963篇 |
2010年 | 3092篇 |
2009年 | 2875篇 |
2008年 | 2636篇 |
2007年 | 2267篇 |
2006年 | 1996篇 |
2005年 | 1780篇 |
2004年 | 1426篇 |
2003年 | 1166篇 |
2002年 | 1035篇 |
2001年 | 904篇 |
2000年 | 701篇 |
1999年 | 562篇 |
1998年 | 501篇 |
1997年 | 375篇 |
1996年 | 406篇 |
1995年 | 353篇 |
1994年 | 323篇 |
1993年 | 282篇 |
1992年 | 286篇 |
1991年 | 229篇 |
1990年 | 192篇 |
1989年 | 164篇 |
1988年 | 148篇 |
1987年 | 143篇 |
1986年 | 126篇 |
1985年 | 145篇 |
1984年 | 125篇 |
1983年 | 88篇 |
1982年 | 92篇 |
1981年 | 78篇 |
1980年 | 62篇 |
1979年 | 44篇 |
1978年 | 39篇 |
1977年 | 36篇 |
1976年 | 34篇 |
1974年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
13.
目的基于人类免疫缺陷病毒Ⅰ型(HIV-1)感染者外周血单个核细胞(PBMCs)中HIV-1总DNA和RNA定量检测结果对感染细胞内病毒的转录活性进行区分。方法采集2017年10月至2018年12月于哈尔滨医科大学附属第四医院感染科就诊的HIV-1感染者血液样本,分离PBMCs细胞,采用PCR荧光探针法对PBMCs细胞内HIV-1总DNA和RNA进行定量检测,并计算两者比值(Ratio)。根据Ratio值筛选出HIV-1转录活跃组样本和相对非活跃组样本,另外选择健康人PBMCs样本作为对照组。对3组样本进行基因转录组表达谱检测以及人口特征差异性检验,并对基因表达谱检测结果进行主成分分析以验证对3组样本病毒转录活性区分的准确性。结果从60例感染HIV-1患者的PBMCs样本中筛选出HIV-1转录活跃组样本(10例)和相对非活跃组样本(11例),另外选择6例健康人PBMCs样本作为对照组。其中转录活跃组样本Ratio值为165.2~738.93,平均为(339.27±189.68);相对非活跃组Ratio值为4.67~42.39,平均为(17.65±11.78)。转录活跃组和相对非活跃组样本间的CD4+T细胞计数(P=0.049)和Ratio值(P<0.001)差异均具有统计学意义;3组样本年龄(P=0.989)和性别(P=0.650)分布差异无统计学意义。对3组样本的PBMCs基因表达谱主成分分析结果显示:对照组与HIV-1感染者(包括转录活跃组和相对非活跃组)间区分明显。转录活跃组和相对非活跃组间有部分样本重合,同时结果也显示当HIV-1感染者的CD4+T淋巴细胞计数与健康人无显著差异时,其细胞内的基因表达与健康人接近。结论基于HIV-1总DNA和RNA定量检测结果及两者间比值可以较好地区分PBMCs内病毒转录活性。HIV-1感染细胞内部病毒的不同转录激活状况可导致其基因表达谱的异质性。 相似文献
14.
15.
《Transfusion Clinique et Biologique》2022,29(1):94-97
Dynamic monitoring ABO chimera including erythroid ABO antigen and anti-A/B is crucial to not only assess the status of erythroid engraftment but also achieve personalized safety transfusion in patients post ABO incompatible hematopoietic stem cell transplantation. Transfusion support for ABO incompatible (ABOi) HSCT patients after achieved complete alteration to donor origin still remains cautious because the instant hematopoietic status on these transplant patients possibly returned to patient origin derived from early disease relapse and graft loss or failure. We reported that reemergent anti-B in a female patients (donor/patient: B/O) at the early phase after achievement complete donor type were not effectively found from partial automatic ABO blood grouping systems, which directly resulted in differential judgement of transplantation stage for about 15 days and disturbed the optimal recommendation on transfusion support. Meanwhile, the solely alteration of ABO chimera was found and earlier than changes of other markers such as MRD diagnosis, chimerism analysis by STR-PCR and sex chromosome assays, which can be an available predictors for bad transplant outcomes such as graft failure. 相似文献
16.
17.
Kerstin Folkerts Natalia Petruski-Ivleva Erin Comerford Michael Blankenburg Thomas Evers Alain Gay Linda Fried Csaba P. Kovesdy 《Mayo Clinic proceedings. Mayo Clinic》2021,96(4):975-986
ObjectiveTo examine the screening rates for kidney damage and function among patients with type 2 diabetes (T2D) and chronic kidney disease stage at diabetes diagnosis using a US administrative claims database.Patients and MethodsThis cohort study used a claims database enriched with laboratory results data. Patients with T2D (defined as 1 inpatient or 2 outpatient claims for diabetes), aged 18 years or older, and with at least 1 year of follow-up enrollment were identified. Patients with type 1 diabetes, kidney disease, or other related conditions at baseline were excluded. We estimated screening rates using laboratory orders for serum creatinine and estimated glomerular filtration rate (eGFR) measurement and urine albumin to creatinine ratio (UACR). Chronic kidney disease severity was reported using the Kidney Disease: Improving Global Outcomes classification based on laboratory results.ResultsA total of 1,881,447 patients with T2D were eligible for analysis. Mean ± SD age was 63.1±13.1 years; 947,150 patients (50.3%) were male. Serum creatinine tests were ordered within 14 days of the index date among 290,722 patients of 622,915 (46.7%) patients with newly-recognized T2D. Overall, 1,595,964 patients (84.8%) had at least one serum creatinine test ordered during the 1-year follow-up period. Fewer patients received a UACR test during follow-up (814,897 [43.3%]). Less than half of all patients with T2D received a laboratory test order for both serum creatinine and urine albumin measurements during the follow-up period.ConclusionPhysicians treating patients with diabetes are selectively adhering to chronic kidney disease screening guidelines, as indicated by high rates of eGFR testing, but less frequent UACR testing. Despite recommendations to monitor both eGFR and UACR, less than half of patients were screened for albuminuria during the 1-year follow-up. 相似文献
18.
19.
Collagens are the most abundant proteins in the extracellular matrix. They provide a framework to build organs and tissues and give structural support to make them resistant to mechanical load and forces. Several intra‐ and extracellular modifications are needed to make functional collagen molecules, intracellular post‐translational modifications of proline and lysine residues having key roles in this. In this article, we provide a review on the enzymes responsible for the proline and lysine modifications, that is collagen prolyl 4‐hydroxylases, 3‐hydroxylases and lysyl hydroxylases, and discuss their biological functions and involvement in diseases. 相似文献
20.
Tetsuji Terazawa Takeshi Kato Masahiro Goto Katsuya Ohta Shingo Noura Hironaga Satake Yoshinori Kagawa Hisato Kawakami Hiroko Hasegawa Kazuhiro Yanagihara Tatsushi Shingai Ken Nakata Masahito Kotaka Masayuki Hiraki Ken Konishi Shiro Nakae Daisuke Sakai Yukinori Kurokawa Toshio Shimokawa Taroh Satoh 《The oncologist》2021,26(1):17-e47
Lessons Learned
- Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS wild‐type unresectable colorectal cancer.
- It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens.